Research programme: stem cell therapy - Jeil Pharmaceutical
Latest Information Update: 31 Aug 2023
At a glance
- Originator Jeil Pharmaceutical
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Parkinson's disease
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Age-related macular degeneration in South Korea (IV)
- 31 Aug 2023 Discontinued - Preclinical for Parkinson's disease in South Korea (IV)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in South Korea (IV)